Abstract
SummaryAntibiotics are over-prescribed for upper respiratory tract infection. Cefaclor is less damaging to commensal flora than some other antibiotics and has fewer gastrointestinal effects. A meta-analysis was performed to determineif the efficacy of cefaclor in the treatment of upper respiratory tract infection was similar to other agents. A total of 4320 patients received cefaclor and 4953 patients received a comparator in 63 studies. Three trials reported a statistically significant difference in efficacy in favour of cefaclor, two compared with penicillin V. In two trials, bacteriological efficacy was reduced compared with co-trimoxazole and co-amoxiclav but clinical efficacy was not significantly different. Meta-analysis suggested significantly lower efficacy for cefaclor than comparators (χ2 6, p<0.03) but there was a significant heterogeneity. Application of the quality index rendered both the difference in efficacy and the heterogeneity non-significant. There was no significant difference in efficacy between amoxycillin, cefixime or cefuroxime axetil and cefaclor. Cefaclor remains an appropriate treatment of upper respiratory infection in view of its safety, reduced effect on colonization resistance and cost.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.